Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas

Summary

The purpose of this study is to determine whether a medication, fluvastatin, can change melanoma to a state that is less likely to metastasize or recur. Fluvastatin is experimental in this setting because it is not approved by the Food and Drug Administration (FDA) for treatment or prevention of melanoma. However, fluvastatin has been approved by the FDA for treating high cholesterol.

Timeline

Start

2020-11-06

Primary completion

2021-04-01

Completion

2021-04-01

Drugs

Indications